With pressure mounting on drugmakers to make clinical trial data more transparent, Pfizer has started to take steps to open up its results, unveiling more concrete details and a timeline for adoption this week.
Pfizer has always been proud of its design of Viagra, which has become known worldwide for its blue color and diamond shape. It thinks enough of it that it is fighting a pitched legal battle in Korea with drugmaker Hanmi Pharmaceutical over the shape of Hanmi's generic, which has grabbed nearly half the market there.
The past few weeks have seen a spate of pharma manufacturing cuts, with Actavis, Merck and Pfizer all whacking jobs. And Pfizer has continued its busy end to 2013 by revealing it is to close a packaging plant in Ireland, laying off 150 workers in the process.
Pfizer is shedding 150 employees at its facility in Newbridge, Ireland. The company says the cuts are needed as generic competition continues to eat away at its revenues. The move comes just two weeks after the U.S. drugmaker targeted a plant in Puerto Rico for closure.
Pfizer likes the growth potential in the over-the-counter niche, and so it keeps piling new products onto the unit from around the world, ignoring investors who would like to it unload the business and share the wealth.
When Pfizer began its virtual trial in 2011, the technology it used was at the forefront of innovation in clinical research. Yet two years later, some of the ideas are already looking dated, with the rise of smartphones meaning Pfizer now foresees participants using their own devices, instead of dedicated tools.
No one ever climbed the industry ladder without getting some help along the way. And for women, including many of the accomplished top performers in this group, that can be especially important....
In the 20 months since the White House unveiled its $200 million Big Data R&D initiative, the field has matured and begun to fulfill its potential. Now the government has inked a batch of data-related projects and signed up Eli Lilly, Novartis and Pfizer as partners.
Pfizer and its much-discussed palbociclib lead the way in the race to cash in on the blockbuster potential of a new pathway to treat breast cancer, but Novartis' rival drug has stealthily closed the gap, promising to compete much sooner than expected.
Pfizer's last quarter reflected ongoing drag from generic competition, and so the drugmaker keeps whittling away at costs where it can. The latest is its manufacturing operations in Puerto Rico, which have already been slimmed down in recent years.